Etesevimab

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

COVID-19SARS-CoV2

Phase 2

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

CompletedNCT04634409

Eli Lilly and CompanyCOVID-19

Start: 2020-10-29End: 2021-10-18Updated: 2022-07-01

Phase 3

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff

CompletedNCT04497987

Eli Lilly and CompanyCOVID-19, SARS-CoV2

Start: 2020-08-02End: 2021-05-20Updated: 2022-02-04

Related Papers

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19.

2024-09-041 citations

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.

2024-01-305 citations

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019

Open Forum Infectious Diseases2022-02-0242 citations

Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial.

2021-11-066 citations

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.

2021-08-1029 citations

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

JAMA2021-06-03208 citations